CliffBio
small molecule

CELEXA

CITALOPRAM HYDROBROMIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCELEXA
Active ingredientCITALOPRAM HYDROBROMIDE
StrengthEQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2000
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CELEXA patent cliff — loss of exclusivity — | CliffBio